Recounting what an executive did while on sabbatical wouldn’t normally fit into our editorial model. That is, unless that executive is Richard Bagger, J.D., EVP of corporate affairs and market access for Celgene.

How long should a CEO stay in the job? Some experts say the best scenario for a CEO whose performance is declining is to get going while the going is still good. In other words, leave while they are at the peak of their performance, just before the decline.

When Joseph Papa took over Valeant Pharmaceuticals in May 2016, the company was in turmoil. We catch up with Papa and see how he’s coming with what he calls “the turnaround opportunity of a lifetime.”

Important lessons learned from the 2014 #SaveJosh social media firestorm that engulfed Chimerix, as well as the company’s former CEO, Ken Moch.

A behind the scenes look into the educational planning for the 2018 BIO International Convention in Boston.

How do we best predict who or what might have a big impact on the biopharma industry in 2018? Although there are no guarantees with this kind of prognostication, we felt seeking the opinions of experienced top biopharma executives would be a good place to start.

I admit I have always taken pleasure in pondering what the future might hold and thus relish opportunities to watch TED Talks or read books by futurists like Ray Kurzweil. So when John Cumbers, Ph.D., and Karl Schmieder asked if I’d be willing to preview their book, What’s Your Bio Strategy? prior to publication, I was all in.

In last’s year’s manufacturing outlook we delved into biopharma’s manufacturing capacity crunch. While lack of manufacturing capacity remains a challenge for the industry, the future of biopharma manufacturing has never looked so bright, and there are a variety of reasons why.

Merck’s VP and head of neuroscience research, Darryle Schoepp, shares insight as to why there is increased interest in developing therapeutics targeting neurodegenerative diseases.